Integrase Strand Transfer Inhibitors in HIV TherapyReportar como inadecuado

Integrase Strand Transfer Inhibitors in HIV Therapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Infectious Diseases and Therapy

, Volume 2, Issue 2, pp 83–93

First Online: 19 November 2013Received: 02 October 2013


HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S. Food and Drug Administration, health practitioners may soon have access to three integrase strand transfer inhibitors to treat individuals living with HIV. Here, we review the use of raltegravir, elvitegravir, and dolutegravir for use in first- and second-line HIV treatment regimens and the issue of HIV resistance against integrase inhibitors.

KeywordsDolutegravir Elvitegravir HIV Infectious disease Integrase inhibitors Raltegravir Resistance Sequencing Electronic supplementary materialThe online version of this article doi:10.1007-s40121-013-0020-8 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Thibault Mesplède - Mark A. Wainberg


Documentos relacionados